Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells

Liver fibrosis is a common outcome of chronic liver disease and leads to liver cirrhosis and hepatocellular carcinoma. No FDA-approved targeted anti-fibrotic therapy exists. Activated hepatic stellate cells (aHSCs) are the major cell types responsible for liver fibrosis; therefore, eradication of aH...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Hepatology
Auteurs principaux: Oh, Yumin, Park, Ogyi, Swierczewska, Magdalena, Hamilton, James P., Park, Jong-Sung, Kim, Tae Hyung, Lim, Sung-Mook, Eom, Hana, Jo, Dong Gyu, Lee, Choong-Eun, Kechrid, Raouf, Mastorakos, Panagiotis, Zhang, Clark, Hahn, Sei Kwang, Jeon, Ok-Cheol, Byun, Youngro, Kim, Kwangmeyung, Hanes, Justin, Lee, Kang Choon, Pomper, Martin G., Gao, Bin, Lee, Seulki
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4917440/
https://ncbi.nlm.nih.gov/pubmed/26710118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.28432
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires